Wang Zhi, Li Min, Wu Wei-kang, Tan Hong-mei, Geng Deng-feng
Department of Anesthesiology, The Second Affiliated Hospital, Sun Yat-sen University, Guangzhou 510120, People's Republic of China.
Cardiovasc Drugs Ther. 2008 Dec;22(6):443-52. doi: 10.1007/s10557-008-6129-4. Epub 2008 Aug 5.
Ginsenoside Rb1, a major bioactive component of Panax ginseng, bears various beneficial effects on the cardiovascular system. This study investigated whether ginsenoside Rb1 preconditioning has protective effects on myocardial ischemia-reperfusion injury and its potential mechanism.
Rats subjected to 45 min of myocardial ischemia followed by 120 min of reperfusion were assigned to the following groups: sham-operated, ischemia-reperfusion (I/R), ginsenoside Rb1+I/R, wortmannin(a specific PI3K inhibitor)+I/R, wortmannin drug vehicle (dimethyl sulfoxide, DMSO), wortmannin+sham, ginsenoside Rb1+ wortmannin +I/R. Infarct size was assessed by triphenyltetrazolium chloride staining. Plasma creatine kinase (CK), creatine kinase isoenzyme MB (CK-MB), lactate dehydrogenase (LDH), and troponin T levels were also measured. Akt phosphorylation expression was assessed by immunoblotting.
Ginsenoside Rb1 preconditioning reduced infarct size compared with that in the I/R group: 30 +/- 2.6% versus 51 +/- 2.7% (p < 0.01). Ginsenoside Rb1 preconditioning also markedly reduced the plasma CK, CK-MB, LDH and troponin T levels in blood. Akt phosphorylation expression increased after ginsenoside Rb1 preconditioning. These effects of ginsenoside Rb1 preconditioning were significantly inhibited by wortmannin.
This is the first study to demonstrate that ginsenoside Rb1 preconditioning has protective effects on myocardial ischemia and reperfusion injury, partly by mediating the activation of the PI3K pathway and phosphorylation of Akt.
人参皂苷Rb1是人参的主要生物活性成分,对心血管系统具有多种有益作用。本研究探讨人参皂苷Rb1预处理对心肌缺血再灌注损伤是否具有保护作用及其潜在机制。
将经历45分钟心肌缺血并随后进行120分钟再灌注的大鼠分为以下几组:假手术组、缺血再灌注(I/R)组、人参皂苷Rb1+I/R组、渥曼青霉素(一种特异性PI3K抑制剂)+I/R组、渥曼青霉素溶媒(二甲基亚砜,DMSO)组、渥曼青霉素+假手术组、人参皂苷Rb1+渥曼青霉素+I/R组。通过氯化三苯基四氮唑染色评估梗死面积。还测量了血浆肌酸激酶(CK)、肌酸激酶同工酶MB(CK-MB)、乳酸脱氢酶(LDH)和肌钙蛋白T水平。通过免疫印迹评估Akt磷酸化表达。
与人参皂苷Rb1预处理组相比,人参皂苷Rb1预处理减少了梗死面积:30±2.6%对51±2.7%(p<0.01)。人参皂苷Rb1预处理还显著降低了血液中血浆CK、CK-MB、LDH和肌钙蛋白T水平。人参皂苷Rb1预处理后Akt磷酸化表达增加。渥曼青霉素显著抑制了人参皂苷Rb1预处理的这些作用。
本研究首次证明人参皂苷Rb1预处理对心肌缺血再灌注损伤具有保护作用,部分是通过介导PI3K途径的激活和Akt的磷酸化实现的。